Defunct Company
Total Trials
8
As Lead Sponsor
3
As Collaborator
5
Total Enrollment
709
NCT01059071
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Phase: Phase 1
Role: Collaborator
Start: Feb 28, 2010
Completion: May 31, 2015
NCT01245816
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Phase: Phase 3
Role: Lead Sponsor
Start: Mar 31, 2011
Completion: Jun 30, 2013
NCT01349881
S0820, Adenoma and Second Primary Prevention Trial
Start: Aug 23, 2013
Completion: Feb 1, 2032
NCT01483144
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Start: Oct 31, 2013
Completion: Mar 31, 2019
NCT01636128
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Phase: Phase 2
Start: Mar 31, 2014
Completion: Apr 30, 2016
NCT02670356
Study Comparing Fish Oil and Krill Oil
Phase: N/A
Start: Oct 31, 2015
Completion: Jul 31, 2016
NCT02794428
Chemoprevention of Gastric Carcinogenesis
Start: Sep 19, 2016
Completion: Jul 1, 2024
NCT05594563
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
Start: Mar 14, 2023
Completion: May 31, 2028